Retatrutide reviews are overwhelmingly positive on weight loss and consistently cautious on tolerability. Across published trials, the highest dose drove average reductions of roughly 24% of body weight at 48 weeks in phase 2 and up to 28.3% at 80 weeks in the phase 3 TRIUMPH-1 study, with some patients exceeding 30%. The trade-off is gastrointestinal side effects, mainly nausea, that affect a large share of users during dose escalation. One fact frames every honest review: retatrutide is investigational. As of June 2026 it is not approved by the FDA and is legally available only through Eli Lilly clinical trials.
This page synthesizes what the trial data actually shows alongside themes from self-reported user experiences, then gives a straight verdict. It is distinct from a benefits overview. If you want the foundational explainer first, see what is retatrutide.
What retatrutide is, in one paragraph
Retatrutide is a triple hormone receptor agonist developed by Eli Lilly. It activates three receptors at once: GLP-1, GIP, and glucagon. The first two are familiar from tirzepatide. The glucagon arm is the differentiator, because glucagon receptor activity is thought to increase energy expenditure on top of appetite suppression. That mechanism is why some users report a different feel than semaglutide. For the biology, see retatrutide mechanism of action.
Real results: what the trial data shows
The strongest evidence comes from two sources, the phase 2 trial published in the New England Journal of Medicine in 2023 and the phase 3 TRIUMPH-1 results reported in 2026.
Phase 2 (NEJM, 338 adults, 48 weeks)
This randomized, double-blind, placebo-controlled trial enrolled 338 adults with obesity or overweight and no type 2 diabetes. Weight loss was dose dependent and continued climbing through 48 weeks rather than plateauing early.
| Dose | 24-week loss | 48-week loss |
|---|---|---|
| Placebo | -1.6% | -2.1% |
| 1 mg | -7.2% | -8.7% |
| 4 mg | -12.9% | -17.1% |
| 8 mg | -17.3% | -22.8% |
| 12 mg | -17.5% | -24.2% |
At the 12 mg dose, 100% of participants lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15% by 48 weeks. The curves had not flattened at study end, which suggested more loss was possible with longer treatment.
Phase 3 TRIUMPH-1 (2,339 adults, 80 to 104 weeks)
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight plus a weight-related condition, without diabetes. All three doses met the primary and key secondary endpoints. The numbers below reflect the efficacy estimand (results for participants who stayed on treatment).
| Dose | 80-week loss | Pounds lost (avg) |
|---|---|---|
| Placebo | -2.2% | 5.5 lb |
| 4 mg | -19.0% | 47.2 lb |
| 9 mg | -25.9% | 64.4 lb |
| 12 mg | -28.3% | 70.3 lb |
At 12 mg, 45.3% of participants lost at least 30% of their body weight, a threshold that approaches some bariatric surgery outcomes. In a 104-week extension of 532 participants with a starting BMI of 35 or higher who escalated to their maximum tolerated dose, average loss reached up to 30.3%.
Two other phase 3 readouts add context. TRIUMPH-4, in adults with obesity and knee osteoarthritis, reported about 28.7% loss at 68 weeks on 12 mg. TRANSCEND-T2D-1, in people with type 2 diabetes, showed about 16.8% loss at 40 weeks on 12 mg, lower than the non-diabetes cohorts, which mirrors the pattern seen with other GLP-1 drugs in diabetes. Both readouts sit within a broader phase 3 program of eight trials enrolling more than 5,800 participants across obesity, type 2 diabetes, osteoarthritis, sleep apnea, and cardiometabolic outcomes, with most of the remaining results due to report through 2026. For the full study breakdown, see retatrutide clinical trial.
What users actually report
Trial averages are clean. Real-world reports are messier, because most current users are taking compounded retatrutide outside of trials, often without clinical supervision or standardized titration. A 2026 medRxiv analysis of self-reported side effects among Reddit users captured these community themes, with the caveat that self-report is unverified and prone to selection bias.
Recurring patterns from user reviews:
- Fast early appetite drop. Many describe strong satiety within the first week or two, sometimes stronger than they expected from a starting dose.
- Energy that differs from semaglutide. A common theme is more energy or warmth, plausibly tied to the glucagon component, though some report the opposite.
- "Retatrutide tiredness" early on. Fatigue during the first 2 to 3 weeks is frequently mentioned and usually described as fading once the body adjusts.
- Nausea as the top complaint. Consistent with the trials, nausea dominates, and users repeatedly credit slow titration with keeping it manageable.
- Skin sensitivity. Some report a burning or sunburn-like skin sensation, a theme that shows up more in user reports than in published trial summaries.
- Elevated heart rate. A noticeable resting heart rate bump is mentioned, matching the dose-dependent heart rate rise seen in trials.
- Wide outcome spread. Self-reported results range from 20-plus pounds in eight weeks to near non-response, often traceable to inconsistent compounded dosing, reconstitution errors, or peptide degradation from poor storage.
The takeaway from user reviews: the upside can be dramatic, but the experience is far more variable outside controlled conditions. For first-person timelines, see retatrutide week by week and retatrutide before and after.
Side effects: what to expect
Side effects are predictable in type and concentrated during dose escalation. They are overwhelmingly gastrointestinal and mostly mild to moderate. Here is the TRIUMPH-1 safety snapshot by dose.
| Adverse effect | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhea | 25.2% | 34.1% | 32.0% | 13.5% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
| Constipation | - | - | 26.1% | - |
Discontinuation due to adverse events tracked with dose: 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, versus 4.9% on placebo. In the phase 2 trial, discontinuation ranged from 6% to 16% across active doses versus 0% on placebo.
Other documented findings:
- Heart rate. Resting heart rate rose dose-dependently through about week 24, then declined in later weeks of the phase 2 trial.
- Dysesthesia and urinary tract infections. Each occurred in roughly 10% of patients at higher doses in TRIUMPH-1, generally mild to moderate.
- No new signals. Published trials reported no pancreatitis or thyroid malignancy cases, though long-term surveillance is still limited and ongoing.
The practical lesson across both data and user reviews is the same: titrate slowly. Side effects cluster in the escalation phase and ease at maintenance. For deeper coverage, see retatrutide side effects and is retatrutide safe.
How retatrutide reviews compare to tirzepatide and semaglutide
Reviewers frequently rank retatrutide as the most potent of the three on weight loss, with tolerability that is broadly comparable to tirzepatide and arguably more demanding at the top dose. The comparison below is approximate and uses each drug's flagship trial peak figures, which differ in design and duration, so treat it as directional rather than head-to-head.
| Drug | Receptors | Peak avg weight loss (trial) | Status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% (STEP, 68 wk) | FDA approved |
| Tirzepatide | GLP-1 + GIP | ~21% (SURMOUNT-1, 72 wk) | FDA approved |
| Retatrutide | GLP-1 + GIP + glucagon | ~28% (TRIUMPH-1, 80 wk) | Investigational |
The headline gap in this table is approval status. Semaglutide and tirzepatide are approved and prescribable. Retatrutide is not. For detailed matchups, see retatrutide vs tirzepatide and retatrutide vs semaglutide.
Dosing in plain terms
Trials escalated gradually from a low starting dose to a maintenance target, typically over months, to limit GI side effects. The 12 mg dose delivered the most weight loss but also the most nausea and the highest discontinuation rate, so the best dose is the highest one a person tolerates, not automatically the maximum. For structured schedules, see retatrutide dosage and the retatrutide dosing schedule.
The honest verdict
On efficacy, retatrutide reviews are earned, not hype. The phase 3 weight loss figures are the strongest yet seen in this drug class, and the share of patients hitting 30% loss is genuinely notable. The glucagon mechanism may also explain the energy reports that distinguish it from semaglutide in user accounts.
The caveats are real and should weigh heavily:
- It is not approved. As of June 2026, retatrutide is investigational, and approval is not anticipated before 2027 at the earliest. Anything sold outside a trial is compounded and unapproved, with no guarantee of identity, purity, or dose. See when will retatrutide be available.
- Tolerability is a hurdle. Most users will have nausea during escalation, and roughly 1 in 9 stopped the top dose in TRIUMPH-1 due to side effects.
- Long-term data is still maturing. Multi-year safety, durability after stopping, and lean-mass effects are not fully characterized.
Bottom line: the results justify the excitement, but the responsible verdict is to wait for approval and clinician-supervised access rather than chasing compounded vials. If you and a qualified clinician decide it fits your situation once available, the data suggests it can deliver category-leading weight loss for those who can tolerate titration.
FAQ
Is retatrutide FDA approved in 2026?
No. As of June 2026 retatrutide is investigational and not FDA approved. It is legally available only to participants in Eli Lilly clinical trials, and approval is not expected before 2027 at the earliest.
How much weight do people lose on retatrutide?
In phase 3 TRIUMPH-1, average loss on the 12 mg dose was 28.3% at 80 weeks, with up to 30.3% in a longer extension among higher-BMI patients. Phase 2 showed about 24.2% at 48 weeks on 12 mg. Individual results vary widely, especially with compounded use.
What is the most common side effect?
Nausea, reported by about 42% of people at the 12 mg dose in TRIUMPH-1. Diarrhea, vomiting, and constipation are also common. Most are mild to moderate and concentrated during dose escalation.
Does retatrutide give you more energy than other GLP-1 drugs?
Some user reviews describe more energy or warmth than on semaglutide, plausibly linked to glucagon receptor activity that may raise energy expenditure. This is a reported theme, not a guaranteed effect, and others report fatigue early on.
Is compounded retatrutide safe?
Compounded retatrutide is unapproved and not quality-assured, so identity, purity, and dosing can vary. Reported non-response and inconsistent results often trace to compounded products. See compounded retatrutide for more.
This article is for informational purposes only and is not medical advice. Talk to a qualified clinician before starting, stopping, or changing any medication.
